Heda Ventures

Heda Ventures is an early-stage venture capital firm established in 2008 and located in San Jose, California. The firm specializes in investing in disruptive innovations within three primary sectors: biotech, healthcare, and IT technology. Heda Ventures targets seed-stage and early-stage companies, aiming to partner with innovative enterprises that exhibit significant growth potential. The firm is dedicated to supporting entrepreneurs and startups in developing transformative businesses that can create new market opportunities and drive meaningful change in their industries.

Lin Xie Ph.D

Managing Partner

Qiang Chen Ph.D

Venture Partner

Haitao Xia

Venture Partner

Zheng Hongbin

General Partner

9 past transactions

Immunowake

Series A in 2022
Immunowake is a biotechnology company dedicated to developing innovative therapies for patients who do not respond to conventional immunotherapies. The company aims to activate the immune system, specifically targeting antigen-specific T-cells, to enhance the body’s ability to recognize and eliminate cancer cells. By focusing on creating a universal cancer vaccine and bi-specific antibodies, Immunowake seeks to improve treatment outcomes while minimizing toxicity. Its research is rooted in recent advancements in cancer immunotherapy, striving to generate safer and more effective therapeutic options for patients with challenging cancer profiles.

LYNK Pharmaceuticals

Series B in 2021
LYNK Pharmaceuticals is a biotechnology company based in Hangzhou, China, specializing in the development of small molecule drugs aimed at treating tumors and autoimmune diseases. Founded in 2017, the company focuses on the discovery and development of innovative medicines in the fields of oncology, immunology, and inflammatory diseases. Its business operations include new drug research, sales, and activities related to patent authorization and transfer.

Lianchuan Bio

Series B in 2020
Lianchuan Bio is a provider of a genomics and precision medicine platform based in China. The company focuses on the application of genetic technology across various healthcare scenarios. Its platform offers genome sequencing and genetic testing programs, allowing healthcare providers to accurately identify target genes. This capability facilitates significant advancements in clinical gene capture, enhancing the effectiveness of precision medicine.

Citcon

Series B in 2019
Citcon is a prominent payment technology company established in 2015, specializing in creating a payment infrastructure that facilitates global merchants in accepting payments from a vast pool of mobile wallet users across various channels, including online, mobile, and in-store. The company's platform offers a secure and user-friendly experience, enhancing contactless shopping and payment processes for consumers and merchants alike. Citcon's open and scalable system enables businesses to seamlessly integrate multiple domestic and international mobile wallets through a single API suite, encompassing comprehensive services from payment processing to fund settlement. Headquartered in Silicon Valley, California, Citcon operates five regional offices across the U.S., Canada, Europe, and Asia, enabling millions of mobile wallet consumers to transact at tens of thousands of merchants worldwide.

MuMec

Seed Round in 2018
MuMec, Inc. is a technology company based in Oakland, California, founded in 2014, specializing in the development of wireless transceiver technologies. The company focuses on creating devices that significantly lower power consumption, enabling long-term operation of sensor nodes using minimal power sources, such as scavenged energy or batteries. MuMec's transceivers are compatible with Bluetooth low energy and LoRa/Sigfox protocols, allowing for innovative applications including wireless audio streaming. By prioritizing energy efficiency, MuMec aims to enhance the battery life of consumer devices and Internet of Things (IoT) applications, contributing to a more sustainable technology landscape.

Paragon Genomics

Series A in 2017
Paragon Genomics, Inc. is a biotechnology company based in South San Francisco, California, founded in 2015. The company specializes in the development and commercialization of polymerase chain reaction (PCR) reagents and components for molecular biology, focusing on ultra-high multiplex PCR-based target enrichment solutions for next-generation sequencing (NGS). Paragon Genomics offers a range of products, including the CleanPlex targeted library kit and specific panels such as the CleanPlex OncoZoom, BRCA1 & BRCA2, and TP53 Panels, which facilitate the amplification of targeted DNA regions for NGS applications. Their proprietary CleanPlex technology is designed to enhance the accuracy, sensitivity, and cost-effectiveness of targeted sequencing assays, addressing various fields such as oncology, infectious diseases, and genomics-guided research, thereby advancing precision medicine and diagnostics.

Symic Bio

Series B in 2017
Symic Biomedical is a biotechnology company based in San Francisco, California, focusing on developing matrix regulator therapeutics. These therapeutics are designed to target and bind to specific sites within the body's extracellular matrix that have been damaged due to injury or disease. By inhibiting pathological inflammatory responses, Symic Biomedical aims to address conditions such as fibrosis, oncology, and diseases of the central nervous system. The company was incorporated in 2012 and operates as a subsidiary of Symic Holdings, LLC.

ScaleFlux

Venture Round in 2017
ScaleFlux, Inc. is a semiconductor company specializing in data flow architecture and computational storage solutions. Founded in 2014 and headquartered in San Jose, California, with additional offices in Beijing, Shanghai, and Hangzhou, the company focuses on enhancing the efficiency of data centers and cloud infrastructures tailored for data-intensive applications. ScaleFlux's innovative products are designed to give users a competitive advantage by optimizing the data pipeline for cloud, artificial intelligence, enterprise, and edge computing. The company's offerings include advanced storage and memory systems that combine compute engines with substantial solid-state storage, facilitating improved performance, efficiency, security, and scalability. To support customer adoption, ScaleFlux provides fully validated firmware, software, and module designs, in addition to its own branded modules, ensuring seamless integration into existing systems.

Citcon

Seed Round in 2017
Citcon is a prominent payment technology company established in 2015, specializing in creating a payment infrastructure that facilitates global merchants in accepting payments from a vast pool of mobile wallet users across various channels, including online, mobile, and in-store. The company's platform offers a secure and user-friendly experience, enhancing contactless shopping and payment processes for consumers and merchants alike. Citcon's open and scalable system enables businesses to seamlessly integrate multiple domestic and international mobile wallets through a single API suite, encompassing comprehensive services from payment processing to fund settlement. Headquartered in Silicon Valley, California, Citcon operates five regional offices across the U.S., Canada, Europe, and Asia, enabling millions of mobile wallet consumers to transact at tens of thousands of merchants worldwide.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.